New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:02 EDTACTGAcacia reaches settlement with Mallinckrodt over Exalgo
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
06:04 EDTACTGAcacia Research enters into limited settlement with ZTE Corporation
Subscribe for More Information
June 29, 2015
06:02 EDTACTGAcacia Research enter into settlement, patent license agreement with Kyocera
Subscribe for More Information
06:00 EDTACTGAcacia Research enter into settlement, patent license agreement with BMW
Subscribe for More Information
June 22, 2015
06:12 EDTACTGAcacia Research subsidiaries enter into agreement with Mercedez-Benz
In a regulatory filing, Acacia Research disclosed that its subsidiaries Innovative Display Technologies and Delaware Display Group entered into a settlement and license agreement with Mercedes-Benz U.S. International, Inc. and Mercedes-Benz USA, LLC. This agreement resolves patent litigation, Civil Action No. 2:14-cv-00535, pending in the United States District Court for the Eastern District of Texas.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use